KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infection.

Veronica V Rezelj, Jeroen Tolboom, Nina Hertoghs, Jan Serroyen, Mathieu Le Gars, Frank Struyf, Jenny Hendriks, Javier Ruiz Guiñazú, Chelsea McLean

EBioMedicine 127 106270

PMID42085933
PMCIDPMC13158565
DOI10.1016/j.ebiom.2026.106270
发表日期2026-05-05
摘要

摘要

BACKGROUND: Ad26.COV2.S is a recombinant, replication-incompetent human adenovirus serotype 26 (Ad26) vectored vaccine encoding a full-length SARS-CoV-2 spike protein in a prefusion-stabilised conformation. The genes and pathways which are differentially regulated following vaccination with Ad26.COV2.S, how these differ over time, and under different regimens, have not been investigated. METHODS: Gene expression changes were profiled via RNAseq following the first and second dose of Ad26.COV2.S in a subset of individuals with pre-existing SARS-CoV-2 immunity due to prior SARS-CoV-2 infection, included in a randomised, double-blind, Phase 3 study (NCT#04908722). Transcriptional responses induced by a 1- and 2-dose regimen were assessed, each at two different dose levels: the marketed 5 × 1010vp dose level and a lower 1.25 × 1010vp dose level. FINDINGS: Consistent with other vaccine studies, antiviral, interferon, cytokine, and monocyte blood transcriptional modules were differentially regulated one day post-Ad26.COV2.S vaccination. At three days post-vaccination, innate immunity was still transcriptionally active at lower levels than one day post-vaccination. By seven days post-Ad26.COV2.S, increased immunoglobulin gene expression dominated the transcriptome response, indicating a shift towards humoural and B cell responses and activation of adaptive immunity. Transcriptional responses post-Ad26.COV2.S were generally stronger after the first dose versus the second dose. INTERPRETATION: In this study in whole blood, innate and adaptive immune transcripts were upregulated as early as one and seven days post-Ad26.COV2.S, respectively. These findings add to the limited data on innate immune responses to adenovirus-based vaccines in a clinical setting and contribute to understanding the mechanisms behind the adaptive immune responses that may contribute to protective immunity. FUNDING: This study was funded by Johnson & Johnson Innovative Medicine.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。